Oryzon Genomics S A : announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

18 January 2023


ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas



... | January 18, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Madrid ,Douglas Faller ,Namrata Vijayvergia ,Development Agreement ,Us National Cancer Institute ,Nuclear Dynamics ,Cancer Epigenetics Institute ,Fox Chase Cancer Center ,Assistant Chief ,Gastrointestinal Medical Oncology ,Global Chief Medical Officer ,Small Cell Lung Cancer ,About Iadademstat ,Cancer Cell ,Fim Phase ,Cooperative Research ,Cancer Institute ,Oryzon Genomics Sa Stock Exchange ,News ,Information ,Press Release , 8 ,January ,Oryzon ,Nnounces ,First ,Patient ,N ,Collaborative ,Hase ,Hi ,Basket ,Study ,Ith ,Iadademstat ,Patients ,Euroendocrine Ory Es0167733015 ,